DECEMBER 27 (Reuters) – The U.S. Food and Drug Administration (FDA) will make recommendations on how to regulate the use of CBD, a popular cannabis compound, in foods and supplements, The Wall Street Journal says. reported on Tuesday, citing officials familiar with the matter.
After reviewing evidence about the compound’s safety, the FDA will decide in the coming months how it will regulate legal cannabis and whether it will require new agency regulations or new legislation from Congress, according to the report. Decide what
Cannabidiol, or CBD, is a non-psychoactive compound derived from cannabis.
Jazz Pharmaceuticals PLC’s (JAZZ.O) cannabis products, with the exception of Epidiolex, are illegal at the federal level in the United States, but are permitted for use in some states.
Agencies want to know if CBD is safe to eat daily for long periods of time or during pregnancy amid concerns about future fertility, said the head of the FDA’s office developing the FDA’s cannabis strategy. , Patrick Cournoyer told the WSJ.
When asked for comment, the FDA told Reuters it referred to a statement last year that said it was taking steps to improve regulatory pathways for the legal marketing of suitable cannabis and cannabis-derived products.
Reported by Raghav Mahobe, Bangalore. Edited by Devika Symnath
Our Standards: Thomson Reuters Trust Principles.